1171 related articles for article (PubMed ID: 28593216)
1. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
3. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
4. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.
Lähteenvuo M; Tanskanen A; Taipale H; Hoti F; Vattulainen P; Vieta E; Tiihonen J
JAMA Psychiatry; 2018 Apr; 75(4):347-355. PubMed ID: 29490359
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
6. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study.
Tiihonen J; Tanskanen A; Hoti F; Vattulainen P; Taipale H; Mehtälä J; Lähteenvuo M
Lancet Psychiatry; 2017 Jul; 4(7):547-553. PubMed ID: 28578901
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study.
Hatta K; Katayama S; Ishizuka T; Sudo Y; Nakamura M; Hasegawa H; Imai A; Morikawa F; Shimada T; Misawa F; Ozaki S; Fujita K; Watanabe H; Nakamura H; Sugiyama N;
Asian J Psychiatr; 2022 Jan; 67():102917. PubMed ID: 34875558
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
Joo SW; Kim H; Jo YT; Choi YJ; Ahn S; Lee J
Psychol Med; 2023 Jan; 53(1):181-188. PubMed ID: 33855950
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
[TBL] [Abstract][Full Text] [Related]
14. Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
Weiser M; Davis JM; Brown CH; Slade EP; Fang LJ; Medoff DR; Buchanan RW; Levi L; Davidson M; Kreyenbuhl J
Am J Psychiatry; 2021 Oct; 178(10):932-940. PubMed ID: 34256606
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
[TBL] [Abstract][Full Text] [Related]
18. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Taipale H; Tanskanen A; Luykx JJ; Solmi M; Leucht S; Correll CU; Tiihonen J
Schizophr Bull; 2022 Jun; 48(4):774-784. PubMed ID: 35524479
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary.
Takács P; Czobor P; Fehér L; Gimesi-Országh J; Fadgyas-Freyler P; Bacskai M; Rakonczai P; Borsi A; Hegyi R; Németh T; Sermon J; Bitter I
PLoS One; 2019; 14(6):e0218071. PubMed ID: 31194778
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
Tien Y; Wang XY; Huang SC; Huang HP
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38696112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
